European Union governments and healthcare providers have been seeking to maximise the value for money that they can obtain from the acquisition of new treatments for patients.
Consequently, there is a large awareness of the limits that can be placed on patients with regards to having to make financial contributions to their healthcare needs. Payers are now increasingly likely to deny or severely restrict the use of advanced therapies when there is no clear or exceptional economic value for the broader population as they seek to cut costs and decrease public spending and debt.
Current models have been based on medicines designed to treat an entire patient population, and the economic value of a specific medicine has traditionally been analysed through a comparison with other treatment alternatives or palliative care.
This session will examine different strands of this issue.